© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
ADA 2017: CV Complications of Diabetes
June 13th 2017
A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.
ADA 2017: Insulins go Head-to-Head
June 12th 2017
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
ADA 2017: Oral Agents Under Review
June 12th 2017
When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.
T2DM: Intensifying Rx When Diet, Lifestyle and OADs Aren't Enough
May 15th 2017
A how-to overview of how to advance therapy for hyperglycemia and ASCVD risk factors in patients with T2DM.
Self-monitoring Blood Glucose in T2DM: It's Essential
May 15th 2017
Self-monitoring of blood glucose is critical for all patients with T2DM and their physicians.The numbers help modify behavior and Rx.
7 Top Diabetes Apps for Primary Care
May 11th 2017
Seven top diabetes apps for PCPs include insulin calculators, Rx algorithms, comorbidity support, and patient tracking tools.
Multidisciplinary Asthma Care: It Takes a Village
October 29th 2015
Effective asthma care requires attention to comorbidities, complications, and human characteristics of each patient. Speakers at CHEST 2015 described "the village."
Clinical Evolution in Asthma and COPD
October 29th 2015
New approaches discussed at CHEST 2015 ranged from the impact of bariatric surgery on asthma control to endobronchial valve placement in COPD.
Emerging Pharmacotherapy in COPD: Update from CHEST 2015
October 29th 2015
In a well-attended session at CHEST 2015 a number of promising new therapies for treating COPD were reviewed by study authors.
Safety of COPD Medications: Current Evidence
October 28th 2015
COPD is one of the primary lung diseases seen in primary care. A CHEST 2015 panel session reinforced that treatment is often a risk/benefit balance.